The immunological findings defined CFS as a low-grade inflammatory disease, indicated by enhanced production of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and nuclear factor kappa B (NF-B), dysregulated cytokine levels (increased levels of IL-1, IL-4, IL-5, IL-6, and IL-12 and decreased levels of IL-8, IL-13, and IL-15), autoimmune reactions, oxidative and nitrosative stress, reduced levels of antioxidant markers, mitochondrial dysfunction, increased translocation of Gram-negative bacteria, and altered antiviral response elements (i.e
Zhang H, Liu H, Zhou L, Yuen J, Forman HJ
Energy improvements from the B12 component are often felt within the first few days
Moreover, potential bias and confounding factors were identified in the assumption that patients who develop irAEs remain on treatment longer and hence have a better outcome than their counterparts, and as such, could only be attributed to guarantee-time bias [74, 75]